In the subsequent years, additional results from single-center trials demonstrated sustained remissions in patients treated with CD19 CAR-T, including adults and children with B-ALL101,102 and adults with B-NHL or CLL.103,104 The successful responses in these pivotal trials prompted collaborations between scientists, clinicians, and biopharma companies to further develop and implement this treatment, ultimately acquiring the necessary regulatory approvals. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.